Recently a renowned pharma company has received approval from the USFDA for a vital cholesterol-lowering drug. Read on to know more. Hyperlipidemia is one of the main causative factors for cardiovascular disease in patients with significant comorbidities. The need for a suitable, safe, and effective lipolytic agent for managing hyperlipidemia in patients is very crucial.
Recently, a pharma giant has received approval from the USFDA for marketing fenofibrate capsules, indicated to reduce cholesterol and triglycerides in the blood. Drug characteristics The drug characteristics are described in Table 1 Table 1. Characteristics of fenofibrate Indications Primary hypercholesterolemia or mixed dyslipidemia Severe hypertriglyceridemia Dosage and administration The initial dose of fenofibrate should be 134 mg once daily for primary, or mixed dyslipidemia. Severe hypertriglyceridemia: The…
